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Growing evidence indicates targeting PKCi may be effective in treating Hedgehog-dependent cancers.
In this issue of Cancer Cell, Justilien and colleagues present the surprising finding that PKCi promotes
Hedgehog ligand production and lung squamous cell carcinoma growth through SOX2, rather than the
canonical transcription factor GLI.Hedgehog (HH) signaling controls the
morphogenesis of a panoply of organs
by regulating the proliferation and differ-
entiation of stem cells (Briscoe and The´r-
ond, 2013). Because HH regulates key
pluripotency and growth genes such as
MYC, Cyclin D1, Nanog, and BMI1, it
comes as no surprise that alteration of
the HH pathway drives tumor growth.
Although current HH pathway antagonists
are quite effective in certain tumor con-
texts, recent advances in cancer-associ-
ated signaling pathways show a complex
and incomplete picture as to the potential
for ‘‘typical’’ pathway inhibitors (Atwood
et al., 2012).
Tumorigenic HH signaling operates
through cell-intrinsic mutations that cause
inappropriate pathway activation or by
autocrine/paracrine events where the
tumor produces HH ligand to feed itself
or adjacent growth factor-producing
stroma (Figure 1). Before HH is competent
to act, the ligand undergoes autoproteo-
lytic cleavage and dual lipid modifications
to convert to its active form (Briscoe and
The´rond, 2013). HH acyl transferase
(HHAT) partly controls production of
active HH by adding a palmitoyl moiety
to the amino-terminus of the ligand after
cleavage, whereas a separate enzyme
adds a cholesterol moiety to the C termi-
nus. The dual lipid modified HH is trans-
ported to the cell surface where Dis-
patched1 (DISP1) regulates its release.
After activation and secretion, HH binds
to its target cell and inhibits the trans-
membrane receptor Patched1, catalyz-
ing the activation of signal transducer
Smoothened (SMO) and translocation of
GLI transcription factors to the nucleus
to amplify oncogenic gene expression.
Therapeutic inhibition of SMO effec-
tively suppresses tumors driven by cell-
intrinsic mutations, such as basal cellcarcinoma (BCC) and medulloblastoma
(Atwood et al., 2012). Vismodegib,
a recently approved SMO antagonist,
commands a high response rate in pa-
tients with basal cell nevus syndrome
that predisposes them to develop hun-
dreds of BCCs, whereas patients with
locally advanced or metastatic BCCs
show a lower response rate. Patients
with more invasive paracrine-driven HH
tumors, such as small cell lung or pan-
creatic cancer, show little to no respon-
siveness despite evidence of pathway
inhibition. Why targeting the HH pathway
would lead to such disparate outcomes
remains unclear; however, identifying
new targets that can act in both cell-
intrinsic and autocrine/paracrine tumor
proliferation may provide novel thera-
peutic strategies to treat both tumor
types.
Atypical Protein Kinase C lambda/iota
(PKCi) plays a central role in determining
cell polarity, a fundamental property
of cells and tissues that results from
the differential distribution of cellular
components (proteins, lipids, RNA, and
organelles) by promoting asymmetric
functions including oriented cell division,
cell recognition, and cellular adhesion
(Roignot et al., 2013). Apico-basolateral
polarity stems from PKCi-dependent
regulation of vesicle movements through
asymmetric control of the actin cyto-
skeleton, resulting in vectorial transport
of nutrients and signals that play critical
roles in the morphogenesis of most
multicellular organisms. Loss of PKCi,
or the polarity pathways it interacts
with, can lead to abnormalities in cell
polarity, epithelial-to-mesenchymal tran-
sition, and cancer invasiveness.
Apart from polarity signaling, a distinct
role for PKCi as an oncogenic kinase
in HH signaling has emerged. PKCi hasCancer Cell 25,been implicated in tumors with cell-
intrinsic HH signaling, such as BCCs,
where it phosphorylates the zinc finger
domain of GLI1 to activate DNA binding
and transcriptional activity (Figure 1A)
(Atwood et al., 2013). Because PRKCI
(the gene that encodes PKCi) is a GLI
target gene, higher GLI1 activity produces
more PKCi, which feeds back into the
system to amplify HH pathway activation
independently of SMO to feed tumor
growth. BCCs that have become addicted
to PKCi are vulnerable to pharmacolog-
ical inhibition of kinase activity, which
results in pathway suppression and the
blockade of tumor growth. PKCi has
also been implicated as an oncogene in
non-small cell lung cancer (NSCLC),
although the link between PKCi and HH
signaling in this predominantly ligand-
driven tumor remained unexplored until
now (Regala et al., 2005).
In this issue of Cancer Cell, Justilien
et al. (2014) show how PKCi maintains
cancer stem cell-like properties of lung
squamous cell carcinoma (LSCC), an
NSCLC subtype (Justilien et al., 2014).
LSCC oncospheres displayed increased
PKCi activation, which correlated with
activation of the HH pathway, as as-
sessed by RNA sequencing from PKCi-
deficient oncospheres and pharma-
cological agents that target either PKCi
or SMO suppressed oncosphere growth.
Interestingly, the expression of the
HH component HHAT was also depen-
dent on PKCi, suggesting a novel regu-
latory mechanism to control HH ligand
production. Both HHAT and DISP1 have
been shown to be required for the growth
of NCSLC tumor cells and xenografts
(Rodriguez-Blanco et al., 2013). Similarly,
RNA knockdown of PKCi, GLI1, or HHAT
in orthotopic tumors originating from
LSCC oncospheres significantly reducedFebruary 10, 2014 ª2014 Elsevier Inc. 133
Figure 1. PKCi-Dependent Activation of the HH Pathway
(A) PKCi phosphorylates and activates GLI1 to amplify target gene expression in basal cell carcinoma
(BCC), a cell-intrinsic tumor with HH pathway mutations in PTCH1 or SMO. Blue denotes inactive protein,
whereas red is active.
(B) PKCi promotes HHAT-mediated HH ligand production by phosphorylating and activating SOX2,
which binds to the HHAT promoter in HH-driven autocrine/paracrine lung squamous cell carcinoma
(LSCC) tumors.
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Previewstumor take rate and decreased tumor
size.
In addition, the authors found that
PRKCI is frequently co-amplified and
overexpressed in LSCC tumors on the
3q26 amplicon with SOX2, a master
regulator of stem cell maintenance.
Chromatin immunoprecipitation of SOX2
showed occupancy of the HHAT pro-
moter and loss of SOX2 significantly
decreased HHAT mRNA and protein
levels suggesting a novel link between a
stem cell gene and HH pathway acti-
vation that drives LSCC tumor growth.
Surprisingly, SOX2 serves as a substrate
for PKCi, with phosphorylation occurring
adjacent to the HMG DNA-binding re-
gion. SOX2 phosphorylation enhanced
binding to the HHAT promoter, increased
expression of HH target genes, and
augmented growth of oncospheres (Fig-
ure 1B). Whether PKCi-dependent phos-
phorylation of SOX2 controls stem cell134 Cancer Cell 25, February 10, 2014 ª2014maintenance or growth of cell-intrinsic
HH pathway tumors such as BCCs re-
mains to be determined.
This new work reinforces two new
aspects of PRKCI biology. First, PKCi
has now been implicated in two different
HH-driven tumors, because NSCLC
growth shows both cell-intrinsic and auto-
crine/paracrine type signaling (Bermudez
et al., 2013; Yuan et al., 2007). This has
clinical importance in that targeting
SMO appears only to be an effective
therapy for cell-intrinsic, but not para-
crine, HH-dependent tumors. By con-
trast, pharmacological inhibition of PKCi
may prove useful to treat a variety of
HH cancers, because targeting PKCi
appears effective in paracrine-driven
ovarian cancer (Wang et al., 2013). Sec-
ond, although PKCi clearly regulates
cortical trafficking in polarizing cells,
PKCi also operates to regulate nuclear
functions by controlling the affinity ofElsevier Inc.specific transcription factors to chro-
matin. This report adds SOX2 to a
growing list of transcription factors regu-
lated by PKCi, which includes GLI1.
Whether PKCi-dependent regulation of
transcription factors plays similar roles in
normal and tumor biology remains to be
investigated. In any case, the emerging
data implicating ‘‘atypical’’ PKCi in
HH cancer biology suggests that PKCi
involvement may be the rule rather than
the exception.
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